150
Participants
Start Date
October 16, 2023
Primary Completion Date
May 31, 2026
Study Completion Date
July 31, 2029
Tirzepatide
Administered SC
Placebo
Administered SC
Barry J. Reiner, MD, LLC, Baltimore
Azienda Ospedaliero Universitaria Maggiore della Carità, Novara
CenExel iResearch, LLC, Decatur
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna
Aventiv Research Inc, Columbus
PriMED Clinical Research, Dayton
M Health Fairview - Delaware Clinical Research Unit (DCRU), Minneapolis
Nemocnice Jihlava, Jihlava
Washington University School of Medicine, St Louis
Cotton O'Neil Diabetes & Endocrinology, Topeka
Yitzhak Shamir Medical Center, Beer Yaacov
Pennington Biomedical Research Center, Baton Rouge
Solaris Clinical Research, Meridian
Azienda Ospedaliera Universitaria Di Messina G. Martino, Messina
Vanderbilt Health One Hundred Oaks, Nashville
Emek Medical Center, Afula
Rambam Health Care Campus, Haifa
Schneider Children's Medical Center, Petah Tikva
Sheba Medical Center, Ramat Gan
Soroka Medical Center, Beersheba
Shaare Zedek Medical Center, Jerusalem
Alberta Diabetes Institute, Edmonton
The Wharton Medical Clinic Clinical Trials Inc, Hamilton
The Hospital for Sick Children, Toronto
CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi
ReFit Clinic, Olomouc
Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava
Fakultni nemocnice v Motole, Prague
Fakultni nemocnice Kralovske Vinohrady, Prague
Instytut Diabetologii, Warsaw
Samodzielny Publiczny Szpital Kliniczny nr 1 SUM, Zabrze
Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Uniwersyteckie Centrum Pediatrii im. M. Konop -T, Lodz
Eli Lilly and Company
INDUSTRY